Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 128 clinical trials
The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination

Hypothesis: Infections other than HIV can cause LN inflammation and collagen damage to the fibroblastic reticular cell network (FRCn), which will lead to CD4 T cell depletion and impaired vaccine responses. This protocol will study yellow fever vaccine (YFV) in two cohorts of people, one from Uganda and the other …

Accepts healthy volunteers
  • 10 May, 2022
  • 1 location
BATs Treatment for Pancreatic Cancer, Phase Ib/II

This protocol will confirm toxicities and estimate the clinical efficacy of combining anti-CD3 x anti-EGFR bispecific antibody (EGFRBi) armed activated T cells (EGFR BATs) given to patients with locally advanced or metastatic pancreatic cancer who have received at least one dose of first line chemotherapy and may have responding, stable …

serum pregnancy test
serum total bilirubin
biliary stenting
  • 19 Apr, 2022
  • 1 location
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT)

This phase I clinical trial evaluates the safety and feasibility of administering NY-ESO-1 TCR (T cell receptor)engineered peripheral blood mononuclear cells (PBMC) and peripheral blood stem cells (PBSC) after a myeloablative conditioning regimen to treat patients with cancer that has spread to other parts of the body. The conditioning chemotherapy …

cancer chemotherapy
positron emission tomography
neutrophil count
  • 25 Mar, 2022
  • 1 location
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

This is a phase I clinical study to evaluate the safety and efficacy of CAR-T infusion preparation in the treatment of CD19-positive relapsed/refractory non-Hodgkin lymphoma.

diffuse large b-cell lymphoma
refractory non-hodgkin's lymphoma
mantle cell lymphoma
  • 05 Jul, 2022
  • 1 location
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

This is a phase II clinical study to evaluate the safety and efficacy of pCAR-19 B cell autologous infusion preparation in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.

  • 05 Jun, 2022
  • 10 locations
Acalabrutinib in Combination With Anti-CD19 Chimeric Antigen Receptor T-Cells (CART) in B-Cell Lymphoma

This phase I/II trial studies the safety of acalabrutinib and axicabtagene ciloleucel in treating patients with B-cell lymphoma. Acalabrutinib may stop the growth of tumor cells by blocking key pathways needed for cell growth. Immunotherapy with axicabtagene ciloleucel is engineered to target a specific surface antigen on lymphoma cells. Acalabrutinib …

diffuse large b-cell lymphoma
measurable disease
large b-cell lymphoma
lymphoma cells
  • 21 Sep, 2022
  • 1 location
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

This phase I trial studies the side effects of huJCAR014 in treating patients with relapsed or refractory B-cell non-Hodgkin lymphoma or acute lymphoblastic leukemia. huJCAR014 CAR-T cells are made in the laboratory by genetically modifying a patient's T cells and may specifically kill cancer cells that have a molecule CD19 …

gilbert's syndrome
hematopoietic stem cell transplantation
burkitt's lymphoma
  • 24 Mar, 2022
  • 1 location
Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma

The purpose of this study is to test the safety and efficacy of AUTO4 a CAR T cell treatment targeting TRBC1 in patients with relapsed or refractory TRBC1 positive selected T-Non-Hodgkin Lymphoma.

gilbert's syndrome
measurable disease
peripheral t-cell lymphoma
hodgkin's disease
  • 22 Mar, 2022
  • 5 locations
A Study of EXP039 Treatment in Subjects With r/r NHL Subjects

This is a single-center, relapsed/refractory B-cell Non-Hodgkin's Lymphoma study to evaluate the safety and efficacy of EXP039 in relapsed and/refractory B-cell Non-Hodgkin's Lymphoma.

  • 28 Jan, 2021
  • 1 location
A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)

This study is a single-armed, open-label, multicenter Phase 1/2 study to evaluate the efficacy and safety of CT103A in subjects with relapsed and refractory MM.

measurable disease
bone marrow procedure
refractory multiple myeloma
neutrophil count
  • 29 Nov, 2021
  • 14 locations